PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Yuting Zhang

Dalian Medical University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · JOURNAL ARTICLE

Exceptional 106-month survival in multiply relapsed small cell lung cancer after sequential anlotinib and short-course sintilimab: a case report

Frontiers in Oncology

A single case report of exceptional long-term survival in multiply relapsed SCLC; while clinically striking, the uncontrolled design, inability to attribute benefit to specific interventions, and lack of comparative data mean this raises hypotheses rather than establishing efficacy.

PreliminaryLung Cancer Research Studies J. Chen Ping Gao

Reported

Overall survival106 months

Cycles of combined anlotinib and…3

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support